PMID- 38191918
OWN - NLM
STAT- MEDLINE
DCOM- 20240207
LR  - 20240326
IS  - 1759-4766 (Electronic)
IS  - 1759-4758 (Linking)
VI  - 20
IP  - 2
DP  - 2024 Feb
TI  - Myasthenia gravis: the changing treatment landscape in the era of molecular 
      therapies.
PG  - 84-98
LID - 10.1038/s41582-023-00916-w [doi]
AB  - Myasthenia gravis (MG) is an autoimmune disorder that affects the neuromuscular 
      junction, leading to muscle weakness and fatigue. MG is caused by antibodies 
      against the acetylcholine receptor (AChR), the muscle-specific kinase (MuSK) or 
      other AChR-related proteins that are expressed in the postsynaptic muscle 
      membrane. The standard therapeutic approach for MG has relied on 
      acetylcholinesterase inhibitors, corticosteroids and immunosuppressants, which 
      have shown good efficacy in improving MG-related symptoms in most people with the 
      disease; however, these therapies can carry a considerable burden of long-term 
      adverse effects. Moreover, up to 15% of individuals with MG exhibit limited or no 
      response to these standard therapies. The emergence of molecular therapies, 
      including monoclonal antibodies, B cell-depleting agents and chimeric antigen 
      receptor T cell-based therapies, has the potential to revolutionize the MG 
      treatment landscape. This Review provides a comprehensive overview of the 
      progress achieved in molecular therapies for MG associated with AChR antibodies 
      and MuSK antibodies, elucidating both the challenges and the opportunities these 
      therapies present to the field. The latest developments in MG treatment are 
      described, exploring the potential for personalized medicine approaches.
CI  - (c) 2024. Springer Nature Limited.
FAU - Iorio, Raffaele
AU  - Iorio R
AD  - Department of Neuroscience, Universita Cattolica del Sacro Cuore, Rome, Italy. 
      raffaele.iorio@policlinicogemelli.it.
AD  - Neurology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, 
      Italy. raffaele.iorio@policlinicogemelli.it.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20240108
PL  - England
TA  - Nat Rev Neurol
JT  - Nature reviews. Neurology
JID - 101500072
RN  - EC 3.1.1.7 (Acetylcholinesterase)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
RN  - 0 (Receptors, Cholinergic)
RN  - 0 (Autoantibodies)
SB  - IM
MH  - Humans
MH  - *Acetylcholinesterase
MH  - Receptor Protein-Tyrosine Kinases/metabolism
MH  - *Myasthenia Gravis/drug therapy/diagnosis
MH  - Receptors, Cholinergic/metabolism
MH  - Autoantibodies
EDAT- 2024/01/09 06:42
MHDA- 2024/02/07 06:43
CRDT- 2024/01/09 00:07
PHST- 2023/12/06 00:00 [accepted]
PHST- 2024/02/07 06:43 [medline]
PHST- 2024/01/09 06:42 [pubmed]
PHST- 2024/01/09 00:07 [entrez]
AID - 10.1038/s41582-023-00916-w [pii]
AID - 10.1038/s41582-023-00916-w [doi]
PST - ppublish
SO  - Nat Rev Neurol. 2024 Feb;20(2):84-98. doi: 10.1038/s41582-023-00916-w. Epub 2024 
      Jan 8.